9 research outputs found
Fatal StevensâJohnson syndrome/toxic epidermal necrolysis induced by allopurinolârituximabâbendamustine therapy
Safety and Efficacy of Bendamustine-Rituximab in Treatment NaĂŻve Symptomatic Follicular Lymphoma: An Institutional Analysis
Bendamustine in Indolent NonâHodgkin's Lymphoma: A Practice Guide for Patient Management
Screening for cardiovascular comorbidity in United States outpatients with psoriasis, hidradenitis, and atopic dermatitis
Reduced Graphene Oxide/Zinc Oxide Nanocomposite: From Synthesis to its Application for Wastewater Purification and Antibacterial Activity
Natural diarylheptanoid compounds from Curcuma comosa Roxb. promote differentiation of mouse myoblasts C2C12 cells selectively via ER alpha receptors
The effects of melatonin supplementation in adjunct with non-surgical periodontal therapy on periodontal status, serum melatonin and inflammatory markers in type 2 diabetes mellitus patients with chronic periodontitis: a double-blind, placebo-controlled trial
Bendamustine, etoposide and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in patients with multiple myeloma
Chemotherapeutic agents without cross-resistance to prior therapies may enhance peripheral blood stem cell collection and improve patient outcomes by exacting a more potent direct anti-tumor effect prior to autologous stem cell transplant. Bendamustine has broad clinical activity in transplantable lymphoid malignancies, but concern remains over the potential adverse impact of this combined alkylator-nucleoside analog on stem cell mobilization. We performed a prospective, non-randomized Phase II study including thirty-four patients with multiple myeloma (MM) (n=34; ISS stage-I[35%], II[29%] and III[24%]; not scored[13%]) to evaluate bendamustineâs efficacy and safety as a stem cell mobilizing agent. Patients received bendamustine (120 mg/m(2) IV d 1,2), etoposide(200 mg/m(2) IV d 1â3) and dexamethasone(40 mg PO d 1â4) (BED) followed by filgrastim (10 mcg/kg/d s.c.; through collection). All patients (100%) successfully collected stem cells (median of 21.60 Ă10(6)/kg of body weight; range 9.24â55.5Ă10(6)/kg), and 88% required a single apheresis. Six non-hematologic SAEs were observed in 6 patients including: neutropenic fever (1, grade 3), bone pain (1, grade 3), and renal insufficiency (1, grade 1). In conclusion, BED safely and effectively mobilizes hematopoietic stem cells